l e t t e r s
Exosomes show potential for cancer diagnostics because they transport molecular contents of the cells from which they originate. Detection and molecular profiling of exosomes is technically challenging and often requires extensive sample purification and labeling. Here we describe a label-free, high-throughput approach for quantitative analysis of exosomes. Our nano-plasmonic exosome (nPLEX) assay is based on transmission surface plasmon resonance through periodic nanohole arrays. Each array is functionalized with antibodies to enable profiling of exosome surface proteins and proteins present in exosome lysates. We show that this approach offers improved sensitivity over previous methods, enables portable operation when integrated with miniaturized optics and allows retrieval of exosomes for further study. Using nPLEX to analyze ascites samples from ovarian cancer patients, we find that exosomes derived from ovarian cancer cells can be identified by their expression of CD24 and EpCAM, suggesting the potential of exosomes for diagnostics.
Exosomes are membrane-bound phospholipid nanovesicles (50-100 nm in diameter) actively secreted by mammalian cells 1 . Renewed interest in exosomes follows recent reports demonstrating that most types of cancer shed large numbers of exosomes that carry molecular information about the parent tumor 2 . Capturing this information without biopsying the tumor could be a useful clinical and research tool. Rapid isolation and analysis of exosomes, however, is challenging, as ultracentrifugation is time consuming 3 , and conventional detection standards, such as western blot analysis and enzyme-linked immunosorbent assays (ELISA), require large amounts of sample and extensive post-labeling processes for detection 2 . Given these limitations, current analytical methods for exosomes are often impractical for experiments that require large throughput or in which the exosome concentration is low.
Here we report a surface plasmon resonance (SPR)-based assay for label-free, high-throughput exosome protein analyses. The system is based on optical transmission through periodic nanoholes [4] [5] [6] [7] rather than total internal reflection 8, 9 as used in commercial SPR systems. We reasoned that plasmonic nanoholes would be an ideal sensing scheme, as their probing depth (<200 nm) can be readily matched to exosome size for improved detection sensitivity, and the transmission setup allows system miniaturization as well as the construction of tightly packed sensing arrays. We therefore designed a new SPR chip, named nano-plasmonic exosome (nPLEX) sensor, that comprises arrays of periodic nanoholes patterned in a metal film. Each array is functionalized with affinity ligands for different exosomal protein markers. With target-specific exosome binding, the nPLEX sensor displays spectral shifts or intensity changes proportional to target marker protein levels. Compared to conventional methods, the nPLEX technology offers highly sensitive and label-free exosome analyses and enables continuous and real-time monitoring of molecular binding. To improve throughput, we further developed an nPLEX imaging system by combining the nanohole chips with a miniaturized imaging setup. This system is readily scalable for massively parallel measurements (10 5 sensing elements).
Large quantities of exosomes were actively secreted by ovarian cancer cells through fusion of multivesicular endosomes with the plasma membrane, and they circulated in various biofluids ( Fig. 1a and Supplementary Fig. 1a,b) . Nanoparticle tracking analysis, which determines the nanoparticle size by analyzing its Brownian motion, showed that exosomes have a unimodal size distribution with an average diameter of 100 nm (Supplementary Fig. 1c) . We designed the nPLEX sensor to achieve label-free detection of exosomes of this size, where the basic sensing unit consists of a periodic lattice of nanoholes patterned in a gold (Au) film. Simulation studies revealed enhanced electromagnetic fields that were tightly confined within exosome size range (Fig. 1b) . We further tuned the field range to overlap with the exosome size by adjusting the nanohole periodicity, thereby maximizing the detection sensitivity (Supplementary Fig. 2) . The design has a lattice of 44 × 32 nanoholes per sensing unit; each nanohole has a hole diameter of 200 nm in diameter and a periodicity of 450 nm made in a 200-nm-thick Au film on a glass substrate ( Fig. 1c and Supplementary Fig. 2 ). For high-throughput analyses, we laid out a 12 × 3 array of sensing units with multichannel microfluidics placed on top (Supplementary Fig. 3) . Each channel had a sample volume of 0.3 µl and spanned three sensing units for triplicate measurements. In a second-generation chip, we implemented 1,089 measurement sites (33 × 33 array) for massively parallel detection (Supplementary Fig. 4) . Built with the same design parameters, this new chip was fabricated label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor l e t t e r s by interference lithography 10 at a wafer scale for high-throughput chip production.
Unlike conventional reflection-based SPR devices, the nPLEX sensor operates in a transmission mode. This scheme made it possible to use a compact collinear optical setup and construct densely packed sensing units (Supplementary Fig. 5a ). Specific binding of exosomes to the nPLEX sensor changed its local refractive index, which can be monitored by measuring either wavelength shifts (∆λ) in light spectrum (spectral detection) or intensity changes (∆p) at fixed wavelength 11, 12 (intensity detection; Supplementary  Fig. 5 ). We employed spectral detection for assay development and optimization and intensity detection, with a portable imaging system, for point-of-care patient sample analyses (Fig. 1d) . Consisting of a laser diode and a complementary metal oxide semiconductor (CMOS) imager, the system offered a large field of view (~25 mm 2 ). The entire nPLEX array (36 sensing units) was imaged simultaneously for parallel detection.
To functionalize the SPR surface, we used a multistep approach. Pre-coating the device surface with a 1:3 mixture of long (MW, 1 kDa) and short (MW, 0.2 kDa) polyethylene glycol (PEG) polymers minimized nonspecific exosome binding (Supplementary Fig. 6 ) and improved surface hydrophilicity. After PEG-coating, we grafted monoclonal antibodies onto the long PEG chains for specific exosome capture. We did all surface modifications by flowing reagents through the microfluidic channels while monitoring the spectral shifts from binding (Fig. 1e) . The functionalized nPLEX chip shows high specificity for exosome capture, with negligible binding when a control antibody was used ( Supplementary Fig. 7) ; these findings were also confirmed by electron microscopy (Fig. 1f) . Parallel detection of 12 potential exosomal markers can be accomplished in <30 min.
Furthermore, the sensor can be regenerated for repeated use by eluting attached antibodies and exosomes (Supplementary Fig. 8 ).
To establish an assay protocol for quantitative exosome analyses, we first used nPLEX to examine exosome binding kinetics. We functionalized the sensor surface with antibodies against CD63, a type III lysosomal membrane protein abundant in and characteristic of exosomes 13 and introduced exosomes derived from a human ovarian cancer cell line (CaOV3) culture (Fig. 2a) . The observed binding constant was ~36 pM, which was markedly lower than that of individual antigen-antibody binding (~1 nM). Such stable binding of the exosomes could be attributed to the multivalent nature of the nPLEX assay (i.e., multiple binding sites per exosome) 14 . We next determined the detection sensitivity of the nPLEX assay. We estimated the concentration of exosomes isolated from CaOV3 culture using nanoparticle tracking analysis. Two nPLEX sensors, functionalized with an anti-CD63 antibody and control antibody, respectively, were used to measure the relative spectral shifts (∆λ CD63 ) against known exosome counts. The titration experiments established the nPLEX limit of detection of ~3,000 exosomes (670 aM) ( Fig. 2b ; see Online Methods for details). The observed sensitivity was 10 4 -fold higher than that of western blot analysis 13 and 10 2 -fold higher than that of chemiluminescence ELISA (Fig. 2b) . The nPLEX platform also facilitated signal amplification through secondary labeling (Fig. 2c) . For instance, when captured exosomes were targeted with spherical Au nanoparticles (diameter, 10 nm), the signal (∆λ CD63 ) improved by 20%. The signal could be enhanced by 300% by using larger, star-shaped Au nanoparticles (diameter, 50 nm; Fig. 2c and Supplementary Fig. 9 ).
To quantitatively detect exosome proteins, we functionalized the nPLEX sensors with antibodies against various targets and measured the associated spectral shifts (∆λ target ) or intensity changes (∆p target ). npg l e t t e r s
Next, we defined the protein level (ξ target ) of the target protein by normalizing the target-associated changes to those of CD63 (i.e., ξ target = ∆λ target /∆λ CD63 = ∆p target /∆p CD63 ). Such normalization accounts for differences in exosome quantities among samples and reports the average level of a target protein per exosome. We applied this method to profile exosomes from CaOV3 and another human ovarian cancer cell line OV90, for various extravesicular markers. Protein levels correlated well (R 2 > 98%) between nPLEX and the gold standard for this analysis, ELISA ( Fig. 2d ), but nPLEX detection was faster, more sensitive and required smaller sample amounts (Fig. 2b) .
The nPLEX assay can also be used to detect intravesicular markers in exosome lysates ( Supplementary Fig. 10 ) and for downstream genetic analyses by releasing captured exosomes from the device. As an example, we retrieved captured exosomes from the anti-CD63 channel by briefly reducing the pH to elute attached antibodies and exosomes (Online Methods and Supplementary Fig. 8 ). The collected exosomes were subsequently assayed by fluorescence quantitative real-time (qRT)-PCR to measure mRNA contents (Fig. 2e) . We used the nPLEX assay to molecularly screen exosomes across different ovarian cancer cell lines. We aimed to identify a molecular signature to detect ovarian cancer exosomes and examine how closely exosomes reflect their cells of origin. We started with antibody profiling of ovarian cancer and other host cell (noncancer) markers (Fig. 3a) , chosen based on prior studies and scientific databases 15, 16 . Cluster analysis of the profiling data revealed four protein marker groups that were expressed in ovarian cancer or benign cells. We then chose a subset of markers, favoring extracellular markers present in ovarian cancer cells or benign cells and markers for which consistent antibody targeting methods had been established (Supplementary Table 1 ). The following putative cancer markers were thus selected: epithelial cell adhesion molecule (EpCAM) 17 ; CD24 (refs. 17,18); cancer antigen 125 (CA-125) 19 ; cancer antigen 19-9 (CA19-9) 20 ; human epidermal growth factor receptor 2 (HER2) 21 ; mucin 18 (MUC18) 22 ; epidermal growth factor receptor (EGFR) 23 ; claudin 3 (CLDN3) 24 . For noncancer cells, these markers were selected: CD45 (leukocyte), CD41 (platelet) and D2-40 (mesothelial cells) 25 .
We next compared the expression of the aforementioned markers in exosomes (Fig. 3b) and the cell lines from which they are derived (Fig. 3c) . The exosomal and cellular protein profiles showed excellent correlation (Pearson coefficient > 0.95), which supports the use of exosomes as cellular surrogates for the selected protein markers. In the tested cell lines, levels of EpCAM and CD24 markers helped to distinguish ovarian cancer exosomes from exosomes derived from benign cells.
Based on our findings, we used nPLEX to detect cancer exosomes in patient-derived ascites (i.e., excess fluid accumulation in the peritoneal cavity 26 ). Ascites is common in ovarian cancer patients and is often tapped for symptomatic relief. We hypothesized that the fluid, which is generally discarded, would contain exosomes and thus allow for molecular diagnostics 26 . We found that unprocessed ascites samples indeed contained large quantities of exosomes (>10 9 exosomes per ml) sufficient for robust nPLEX detection without further enrichment or signal amplification. Therefore, we assayed samples directly after collecting exosomes through a membrane filter with a 0.2-µm size cutoff; both size and western blot analyses confirmed exosome enrichment after filtration (Supplementary Fig. 11) .
We used the 12-channel nPLEX array, with each channel functionalized with different antibodies for EpCAM, CD24, CD63 and IgG control, and imaged the entire 12 × 3 array using the portable imager system ( Fig. 4a and Supplementary Fig. 5 ). After measuring the diffracted light emitted through the nPLEX sensor, we numerically reconstructed the light intensity at the sensor surface (Fig. 4b) Using ascites from cancer patients, the EpCAM and CD24 arrays displayed significant (P < 0.05; two-tailed t-test) intensity changes (∆p) due to cancer exosome capture; in contrast, changes were negligible in ascites from cirrhosis patients (noncancer controls). We corroborated that the protein levels (ξ) of exosomal markers measured by the imager were comparable to those measured by spectral detection (Supplementary Fig. 12) .
We then obtained ascites samples from ovarian cancer patients (n = 20) and noncancerous ascites from cirrhosis patients as controls (n = 10) (Fig. 4c and Supplementary Tables 2 and 3 ) and profiled them using nPLEX (Fig. 4c) . Exosome concentrations estimated by nPLEX using CD63 signal changes were highly heterogeneous between patient and control samples (Supplementary Fig. 13 ) and 
could not conclusively differentiate between cancer patients and control subjects (P = 0.11; two-tailed t-test); it is likely that exosome numbers were highly susceptible to sampling variations (e.g., ascitic drainage procedure). The levels of EpCAM and CD24 per exosome, however, were significantly higher in the ovarian cancer patient samples (P < 0.001 for both markers; two-tailed t-test) than in control groups (Fig. 4c) . Analyses with receiver operating characteristic curves (Supplementary Fig. 14a ) determined the intrinsic accuracy of 93% for EpCAM and 87% for CD24 (Supplementary Fig. 14b ). Pairing protein level profiles of EpCAM and CD24 further increased the diagnostic accuracy to 97%. However, the small number of patient and control samples in our study limit our conclusions regarding the suitability of these proteins as biomarkers for ovarian cancer.
Next, we explored exosome profiling to monitor clinical response or progression during treatment. We recruited ovarian cancer patients (n = 8) undergoing standard chemotherapy (Supplementary Tables 2 and 4) and collected their ascites samples before and after treatment. For both time points, we measured exosomal EpCAM and CD24 levels. A board-certified oncologist (C.M.C.), blinded to the nPLEX data, assigned each subject either responder or nonresponder status based on accepted clinical, laboratory and/or radiologic metrics. We observed that the levels of exosomal EpCAM, CD24 or both decreased among responding patients, whereas levels of these markers increased in nonresponding patients (Fig. 4d) . The cohort was too small for these data to obtain statistical significance.
Rapid, multiplexed protein analysis of exosomes could improve early disease detection and therapy monitoring. The structure of nPLEX-a periodic array of subwavelength apertures in a metal film-generates intense surface plasmons whose extinction depth is comparable to exosome size, making the technology well-suited to sensitive, label-free exosome detection. By integrating the system with miniaturized optics, we created a highly portable platform capable of both rapid and large-scale sensing. We established a quantitative assay protocol that reports both exosome concentrations and exosomal protein levels of extra-and intravesicular protein markers, while consuming only small amounts of specimen. The captured exosomes can be readily eluted from the device for downstream analyses, such as genomic profiling. Together, these approaches will facilitate comprehensive exosomal analyses by yielding both proteomic and genetic information. CD44v9  MAGP2  TSPAN8  TAG-72  TM  FOLR1  HER2  KI67  p53  CEA  PAX8  VEGFR  S6RP  HER3 p-p53 S100-A1 S100 S100-A6
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For research applications, nPLEX could help explore fundamental questions about exosome-mediated intercellular communication and tumor micro-environment 27, 28 . For clinical applications, with further development and validation, nPLEX could be useful for exploring exosomes as a cancer biomarker, for diagnostics and for evaluating tumor response to therapy. Whereas the current study focused on ovarian cancer exosomes in ascites, the nPLEX analysis could readily be extended to exosomes in other bodily fluids (e.g., blood, cerebrospinal fluids and urine).
Several technical modifications could be made to improve nPLEX and accelerate its application for clinical use. First, using lightinterference lithography 10 , we generated a second-generation nPLEX chip that has substantially higher throughput and >1,000 measurement sites. This chip allows for rapid, wafer-scale nanohole patterning, overcoming the limitations of serial chip processing (i.e., focused-ion beam milling). To implement the next-generation nPLEX chip, we are exploring a molecular printing technique 29 (Supplementary Fig. 15 ) for chip surface modification and developing a new imaging setup for signal readout. The resulting system will be a microarray-type sensor for massively parallel detection. Second, we are working to improve signal amplification through secondary labeling with nanoprobes such as gold nanostars of varying size and dimension to further enhance detection sensitivity. This strategy would be particularly useful for on-chip probing of rare exosomal markers (e.g., protein, mRNA, microRNA or DNA) in exosome lysates. Third, large cohorts in prospective trials, such as exosome screening across a spectrum of human illnesses (e.g., other solid tumors, cardiovascular diseases, diabetes, infections), are required to establish the clinical utility of nPLEX. The resulting large data sets could then be critically analyzed as in functional proteomics studies 30 .
MEtHODs
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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AUtHoR ContRIBUtIonS
Microscope setup. A conventional upright microscope (Nikon Eclipse Ci) was used for spectral measurements. A 100 W halogen lamp illuminated individual nanohole arrays through a 10 × microscope objective, and the transmitted light was collected by an optical fiber placed right underneath the nanohole chip. The transmission spectra were analyzed by a miniature fiber-optic VIS-NIR spectrometer (Ocean Optics). The integration time was 2 s and the spectrum was averaged by 5 times.
Portable imaging setup. An integrated CMOS image sensor (Aptina Imaging) was used for imaging measurements. A laser diode at 638 nm with collimating lens and square pattern diffuser was used for illumination. The beam size was adjusted to cover the entire nanohole array. The nPLEX chip was placed above the image sensor less than a 2 mm away and fixed by a plastic holder. The intensities of all the arrays were collected simultaneously and analyzed by a custom-built MATLAB program. The integration time was ~5 msec, and the intensities were averaged by ten times for each image. Exosome isolation and quantification. Cells at passages 1-15 were cultured in vesicle-depleted medium (with 5% depleted FBS) for 48 h. Conditioned medium from ~10 7 cells was collected, filtered through a 0.2-µm membrane filter (Millipore) and concentrated by differential centrifugation as previously described 3, 13 . For exosome collection from clinical samples, ascites samples were filtered through a 0.2-µm membrane filter (Millipore) to remove cells and debris. The filtrates were used directly for exosomal analysis with the nPLEX sensor. For independent measure of exosome concentrations, we used the nanoparticle tracking analysis (NTA) system (LM10, Nanosight). For the quantification by NTA, exosome concentrations were adjusted to obtain ~50 vesicles in the field of view to achieve optimal counting. All NTA measurements were done with identical system settings for consistency.
Sensor surface modification with antibodies. The Au nanohole surface was first coated with a mixture of polyethylene glycol (PEG) containing long active (carboxylated or biotinylated) thiol-PEG and short inactive methylated thio-PEG (Thermo Scientific, Nanocs) (1:3 active: inactive, 10 mM in PBS). After washing, the surface was either briefly activated with EDC/NHS mixture in MES buffer and conjugated to protein A/G (Thermo Scientific, 2 mg/ml) or used directly for binding with neutravidin (Thermo Scientific, 50 µg/ml). Exosome detection with nPLEX sensor. Before introducing exosomes onto the nPLEX sensor, the fluidic channels were flushed with PBS buffer (3 min), and the baseline spectrum was measured. For in vitro assay with exosomes isolated from cell cultures, exosomes were flown to the device at a flow rate of 0.2-2 µl/min. For clinical ascites samples, the filtered ascites were continuously injected at a constant flow rate of 10 µl/min for 15 min. After exosome incubation, the channels were washed with PBST for 5-10 min at a flow rate of 10 µl/min followed by another set of measurements. The measured spectra and transmitted intensities were analyzed by a custom-designed program (Matlab).
SPR analysis.
For the spectral measurements, the spectral peak position was measured using a custom-built Matlab program by fitting the transmission peak to a multi-order polynomial curve. The peak position was monitored and plotted in real-time upon a new input of data file. A minimum detection level (0.036 nm) was determined by three times of the standard deviation of the spectral peak position measured at a steady state for 5 min ( Supplementary  Fig. 7 ). The limit of detection is then calculated by exploration of the minimum detection level to a fitted titration curve shown in Figure 2b . For the intensity measurements, we calculated the transmitted light intensity at the nanoholes by back propagating the measured intensity profiles according to Rayleigh-Sommerfeld diffraction theory 31 . Then, a circular region-of-interest (ROI) was applied to calculate the intensity value of each sensing unit (i.e., a nanohole lattice). The transmitted light intensities were measured before and after exosome binding and the difference was normalized by the initial intensity value.
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